https://orcid.org/0000-0002-5472-224X
References
- Eddy AA, Symons JM. Nephrotic syndrome in childhood. Lancet. 2003;362(9384):629–639. doi:10.1016/S0140-6736(03)14184-0
- Zhao J, Liu Z. Treatment of nephrotic syndrome: going beyond immunosuppressive therapy. Pediatr Nephrol. 2020;35:569–579. doi:10.1007/s00467-019-04225-7
- Thalgahagoda S, Abeyagunawardena S, Jayaweera H, et al. Pulsed vincristine therapy in steroid-resistant nephrotic syndrome. Biomed Res Int. 2017;2017:1757940. doi:10.1155/2017/1757940
- Bakkum L, Willemen AM, Zoetebier L, et al. A longitudinal study on the effects of psychological stress on proteinuria in childhood steroid-sensitive nephrotic syndrome. J Psychosom Res. 2019;121:8–13. doi:10.1016/j.jpsychores.2019.01.011
- Mishra OP, Jain P, Srivastava P, et al. Urinary N-acetyl-beta-D glucosaminidase (NAG) level in idiopathic nephrotic syndrome. Pediatr Nephrol. 2012;27(4):589–596. doi:10.1007/s00467-011-2041-4
- Kimura S, Soria F, D’Andrea D, et al. Prognostic value of serum cholinesterase in non-muscle-invasive bladder cancer. Clin Genitourin Cancer. 2018;16:e1123–e1132. doi:10.1016/j.clgc.2018.07.002
- Albertí J, Martinet A, Sentellas S, et al. Identification of the human enzymes responsible for the enzymatic hydrolysis of aclidinium bromide. Drug Metab Dispos. 2010;38(7):1202–1210. doi:10.1124/dmd.109.031724
- Lampón N, Hermida-Cadahia EF, Riveiro A, et al. Association between butyrylcholinesterase activity and low-grade systemic inflammation. Ann Hepatol. 2012;11(3):356–363. doi:10.1016/S1665-2681(19)30932-9
- Way RC, Hutton CJ, Kutty KM. Relationship between serum cholinesterase and low density lipoproteins in children with nephrotic syndrome. Clin Biochem. 1975;8(1–6):103–107. doi:10.1016/s0009-9120(75)91072-3
- Cattran DC, Feehally J, Cook HT, et al.; Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl. 2012;2:139–274.
- Tesar V, Zima T. Recent progress in the pathogenesis of nephrotic proteinuria. Crit Rev Clin Lab Sci. 2008;45:139–220. doi:10.1080/10408360801934865
- Vaziri ND. Molecular mechanisms of lipid disorders in nephrotic syndrome. Kidney Int. 2003;63(5):1964–1976. doi:10.1046/j.1523-1755.2003.00941.x
- Goto K, Kono K, Fujii H, et al. Clinical value of serum cholinesterase levels in nephrotic syndrome: an observational study. BMC Nephrol. 2022;23(1):128. doi:10.1186/s12882-022-02764-0
- Chu MI, Fontaine P, Kutty KM, et al. Cholinesterase in serum and low density lipoprotein of hyperlipidemic patients. Clin Chim Acta. 1978;85(1):55–59. doi:10.1016/0009-8981(78)90100-6
- Abbott CA, Mackness MI, Kumar S, et al. Relationship between serum butyrylcholinesterase activity, hypertriglyceridaemia and insulin sensitivity in diabetes mellitus. Clin Sci. 1993;85(1):77–81. doi:10.1042/cs0850077
- Alcântara VM, Chautard-Freire-Maia EA, Scartezini M, et al. Butyrylcholinesterase activity and risk factors for coronary artery disease. Scand J Clin Lab Invest. 2002;62(5):399–404. doi:10.1080/00365510260296564
- Hull RP, Goldsmith DJ. Nephrotic syndrome in adults. BMJ. 2008;336:1185–1189. doi:10.1136/bmj.39576.709711.80